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Significance – An Experience from a South Asian Country
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death (SCD) 
in young people worldwide. It is a genetic cardiac disease with a heterogeneous phenotypic 
expression caused by autosomal dominant mutations in contractile sarcomeric proteins. It has a 
prevalence of 1:500 in general population.[1,2]. Conventionally, it is diagnosed by the presence of 
left ventricular (LV) hypertrophy on 2D-echocardiography; however, cardiac magnetic resonance 
(CMR) is increasingly being used as a specific imaging modality.
ABSTRACT
Objectives: Cardiac magnetic resonance (CMR) imaging is very pertinent in the diagnosis and risk stratification 
of patients with hypertrophic cardiomyopathy (HCM). We aimed to assess the patterns of left ventricular (LV) 
hypertrophy, late gadolinium enhancement (LGE), and their prognostic significance in HCM patients in Pakistani 
population, as no such data are available from Pakistan. 
Material and Methods: is was a retrospective, single center study. All patients who had confirmed diagnosis 
of HCM on CMR at Aga Khan University Hospital during the period of 2011–2019 were identified and included 
in the study.
Results: A total of 74 patients were included with the mean age of 45.6 ± 15 years and the majority 71.6 % (n = 53) 
being male. Maximal LV wall thickness was 21.1 ± 5 mm, asymmetrical septal hypertrophy being the most 
common pattern (62.2%, n = 46). LGE was present in 75.7% (n = 56) with most common site being septum plus 
LV free wall (24.3%, n =18). Mean ejection fraction% was found to be lower in patients with LGE (P < 0.001). 
Major adverse cardiac events (MACE) were observed in 40.5% (n = 30). Presence of LGE and right ventricular 
involvement was found to have a statistically significant association with MACE (P value 0.018 and 0.046, 
respectively). In multivariable analysis, only LGE was significantly associated with MACE (odd ratio: 4.65; 95% 
CI: 1.21–17.88).
Conclusion: Asymmetrical septal hypertrophy was the most common pattern of hypertrophy. LGE was present in 
three fourth of the study population and it was significantly associated with MACE.
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CMR is more pertinent not only in the diagnosis of HCM 
but also in predicting the prognosis by detection of late 
gadolinium enhancement (LGE). CMR has an edge over 
echocardiography as it provides more accurate assessment 
of LV function and LV hypertrophy.[3] It can also accurately 
detect the different patterns of LV hypertrophy, that is, 
asymmetric, symmetric, apical, and mid ventricular.
Worldwide, much data are available on the patterns of 
hypertrophy and LGE on CMR in HCM. However, there is 
paucity of data on this topic in our population. is study was 
conducted to assess the patterns of LV hypertrophy and LGE 
on CMR, in HCM patients in Pakistani population. We also 
determined the prognostic significance of LGE in these patients. 
is is the first study of its kind in Pakistani population. As Aga 
Khan University Hospital (AKUH) is the first and the only 
center offering comprehensive CMR services in the country 
since 2011, so this was the best place to conduct such study.
MATERIAL AND METHODS
is study was conducted after approval from the ethical 
review committee. All the patients who had undergone CMR 
at AKUH with the suspected diagnosis of HCM, during the 
period 2011 to 2019 were identified using Health Information 
Management Services. Only those patients were included in 
the study who had confirmed diagnosis of HCM on CMR.
A pre-designed data entry form was filled for each patient 
after reviewing their medical records. Information 
was collected regarding age, gender, clinical features at 
presentation, Electrocardiogram (EKG) findings, echo 
data, and CMR findings. Follow-up data regarding death, 
arrhythmias and hospital admissions for heart failure were 
also collected by reviewing the medical records.
HCM
e diagnosis of HCM was based on the CMR demonstration 
of a hypertrophied LV (wall thickness ≥15 mm), with a non-
dilated cavity in the absence of another cardiac or systemic 
disease that could produce the magnitude of hypertrophy 
evident.
Exclusion criteria
Patients with the diagnosis of cardiac amyloidosis, Fabry’s 
disease, or cardiac sarcoidosis were excluded from the study. 
Similarly, patients with LV hypertrophy due to hypertension, 
aortic stenosis, or athlete’s heart were excluded from the study.
CMR data acquisition
CMR was performed using a 1.5T Siemens Avanto scanner. 
A breath hold steady-state free-precession ECG-triggered 
sequence was used to evaluate global LV and right ventricular 
(RV) function. In each patient, two long axis views (one 
vertical and one horizontal) and two LVOT views were 
acquired. A set of contiguous short-axis views were also 
acquired from the mitral plane to the apex with the following 
parameters: Slice thickness 7 mm, distance factor 25%, 
field of view 34 cm, matrix 192 × 192, flip angle 80, TR/TE 
58.74/1.12, and bandwidth 930 hz/px.
LGE images were obtained 8–10 min after bolus injection 
of gadolinium. Images were acquired in the same views as 
used for cine CMR. e inversion time was optimized to null 
signal from the normal myocardium.
CMR analysis
All the images were analyzed by a reader who was qualified 
and experienced in cardiovascular imaging. e analysis of 
CMR images was done on third party software – Medis Q 
mass. e endocardial and epicardial borders were drawn 
manually on the series of short axis cine slices of the LV at 
end-diastole and end-systole to obtain end-diastolic volume 
and end-systolic volume, respectively. e LV ejection 
fraction (EF) was calculated from the EDV and ESV, and 
presented as percentages to EDV.
LGE analysis was done visually; all tomographic short axis 
LV slices from base to apex were inspected to identify LGE. 
In addition, two chamber, four chamber, three chamber, and 
LVOT views were also inspected for identification of LGE 
visually.
RV involvement was considered when RV free wall thickness 
was >5 mm. Maximal LV wall thicknesses were defined as the 
greatest dimension anywhere within the LV myocardium. 
No definite cutoff for mild, moderate, and severe LV wall 
thickness/hypertrophy is available for CMR. We just 
took the echocardiographic cutoff values which are: Mild 
hypertrophy – male 11–13 mm, female 10–12 mm; moderate 
hypertrophy – male 14–16 mm, female 13–15 mm; and 
severe hypertrophy – male >16 mm, female >15 mm.
LVOT and mid cavity obstruction was assessed visually. 
Similarly, no quantification was done for assessment of 
severity of mitral regurgitation.
Follow-up
Follow-up clinical events were recorded by review of hospital 
records of clinic visits, hospital admissions, and telephonic 
interviews with the patient or a family member, in case the 
patient was unavailable. e clinical events considered were 
death, hospital admissions for heart failure, life-threatening 
arrhythmias, and appropriate Implantable Cardioverter 
Defibrillator (ICD) discharges. All deaths were presumed 
to be cardiac deaths unless a clear non-cardiac cause could 
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be established. Life-threatening arrhythmia was defined as 
documented ventricular tachycardia (VT) or ventricular 
fibrillation (VF) by EKG strips or ICD interrogation.
Statistical analysis
Data were entered and analyzed using the Statistical Package 
for the Social Sciences, version 24.0. Quantitative variables 
were expressed as mean and standard deviation or median 
(interquartile ranges) as appropriate. Qualitative variables 
were expressed as absolute frequencies and percentages. 
Qualitative data were compared using the two test or Fisher’s 
exact test, as appropriate. Continuous data were compared 
using an independent samples t test or the Mann-Whitney 
U-test, depending on their distribution. A two-sided P < 0.05 
was considered statistically significant for all tests.
RESULTS
A total of 74 patients who fulfilled the inclusion criteria were 
included in the study. Baseline clinical and demographic 
characteristics are summarized in Table  1. Mean age was 
45.6 ± 15 years with the majority 71.6 % (n = 53) being 
male. Dyspnea (62.2%, n = 46) was the main symptom at 
presentation, followed by syncope (39.2%, n = 29).
Findings of CMR are shown in Table  2. Maximal LV wall 
thickness was 21.1 ± 5 mm with more than half of patients 
56.8% (n = 42) having severe LV hypertrophy. Asymmetrical 
septal hypertrophy was the most common pattern of 
hypertrophy present in 62.2% (n = 46) of the patients, 
followed by septal and anterior wall hypertrophy (17.6%, 
n = 13). Various patterns of LV hypertrophy are shown in 
Figures 1-5.
LGE was present in 75.7% (n = 56) of the patients 
[Figures  6 and 7] and most common site was septum plus 
LV free wall (32.1%, n = 18), followed by apical site (17.8%, 
n = 10). Most common pattern of LGE was patchy which was 
present in 73.2% (n = 41).
Patients were divided into two groups on the basis of presence 
or absence of LGE [Table  3]. ere was no statistically 
significant difference between two groups on basis of age and 
gender. However, patients with LGE were more likely to have 
systolic dysfunction (P = 0.018) and mean EF was also found 
to be lower in patients with LGE (P < 0.001). Maximal LV wall 
thickness and mean LV mass was also greater in patients with 
LGE (P = 0.001 and 0.016) compared to those without LGE.
Follow-up was available in all patients and mean follow-up 
duration was 39.6 + 27.3 months. Major adverse cardiac 
events (MACE) (Death, heart failure, VT/VF) were observed 
in 40.5% (30/74) of the study population [Table 4].
Table 1: Clinical and demographic characteristics.
Characteristics Number (n=74) Percentage





Family history of sudden 
cardiac death
23 31.1







Chest pain 16 21.6
Table 2: CMR findings in patients with hypertrophic 
cardiomyopathy.













Septum and anterior wall 13 17.6
Symmetric 5 6.8
Mid Ventricular 5 6.8
Apical 5 6.8
RV involvement 12 16.2
Increased LV Mass 57 77
LVOT obstruction 21 28.4
Mid-cavity obstruction 12 16.2
Systolic anterior motion 23 31.1
Mitral regurgitation 18 24.3
LGE 56 75.7
Site of LGE (n=56)




LV free wall 7 12.5







CMR: Cardiac magnetic resonance, LV: Left ventricle, RV: Right ventricle, 
LGE: Late gadolinium enhancement
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Figure  1: A 70-year old male with hypertension presented with 
history of syncope. Cardiac magnetic resonance steady-state free 
precession still frame 3chamber view showing asymmetrical septal 
hypertrophy (arrow). Figure  3: A 71-year old male with history of syncope. Cardiac 
magnetic resonance steady-state free precession still frame 
2chamber view showing mid ventricular hypertrophy (arrow).
Patients were divided into two groups on the basis of presence 
or absence of MACE [Table  5]. e presence of LGE and 
RV involvement was found to have a statistically significant 
association with MACE. In multivariable analysis, only LGE 
was significantly associated with MACE (odd ratio: 4.65; 95% 
CI: 1.21–17.88).
DISCUSSION
is is the first study of its kind from this part of the world, 
describing the patterns of LV hypertrophy and LGE in 
patients with HCM on CMR, and looking at their prognostic 
significance. is will highlight the importance of CMR in 
the diagnosis and management of HCM in our population.
CMR plays a pivotal role in the diagnosis and risk stratification 
of patients with HCM. Due to high resolution, CMR 
determines the LV wall thickness accurately, compared to 
echocardiography. ere are multiple morphological variants 
of HCM which are easily recognized by CMR. Asymmetrical 
septal hypertrophy was the most common morphologic 
presentation of HCM in our series. In this variant 
Figure 4: A 38-year old male with history of chest pain, diffuse T 
wave changes on ECG and normal coronary angiogram. Cardiac 
magnetic resonance steady-state free precession still frame 
2chamber view showing apical hypertrophy (arrow). 
Figure  2: A 55-year old male with history of palpitation and left 
ventricular hypertrophy on echo. Cardiac magnetic resonance 
steady-state free precession still frame short axis view showing 
septal and anterior wall hypertrophy (arrow).
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hypertrophy predominantly involves the septum.[4] Septal 
and anterior wall hypertrophy was the next common pattern 
of hypertrophy. In this variant hypertrophy predominantly 
involves the basal anterior wall and contiguous portion of the 
anterior inter-ventricular septum.[4]
ese findings are consistent with the findings in the 
literature, asymmetric HCM or septal HCM is the most 
Figure 5: A 49-year old female with history of shortness of breath 
and left ventricular hypertrophy but no hypertension or aortic 
stenosis. Cardiac magnetic resonance steady-state free precession 
still frame 4chamber view showing symmetrical hypertrophy 
(arrow).
Figure  6: A 71-year old male with history of syncope. Cardiac 
magnetic resonance late gadolinium image showing apical hyper-
enhancement in mid ventricular hypertrophy variant (arrow).
Table 3: Comparison of patients with and without LGE.
LGE+ LGE− P-value
Age (44±16) (48.3±14.7) 0.43
Gender
Male 43 (81.1%) 10 (18.9%) 0.08
Female 13 (61.9%) 1 (38.1%)
Mean LV mass (g) (231±99) (175±40) 0.016
LV wall thickness (22.3±5.4) (17.5±2) 0.001
EF Mean 62.7±14.1 74.05±5.3 <0.001
EF
>60% 43 (71%) 18 (29%) 0.018*
51–59% 5 (100%) 0 (0%)
<50% 8 (100%) 0 (0%)
LVOT obstruction 10 (47.6%) 11 (52.4%) 0.001
*Fischer’s exact, LGE: Late gadolinium enhancement, LV: Left ventricle, 
EF: Ejection fraction





ICD insertion 33 44.5
Hospitalization 36 48.6
Causes of hospitalization







ICD discharge 11 14.8
Sudden cardiac death 1 1.3
ICD: Implantable cardioverter defibrillator
Figure  7: A 50-year old male with history of palpitation and 
syncope. (a) Cardiac magnetic resonance late gadolinium image 
2chamber view showing hyper-enhancement in the anterior wall 
(arrow). (b) Cardiac magnetic resonance late gadolinium image 
short axis view showing hyper-enhancement in the anterior wall 
and adjacent septum (arrow).
ba
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common morphologic presentation accounting for about 
two thirds of the spectrum.[4,5]
In mid ventricular hypertrophy variant, the hypertrophy 
predominantly involves the mid segments of the left ventricle 
and may result in mid ventricular obstruction.[6,7] It may be 
associated with the formation of an apical aneurysm. is 
variant was seen in small number of patients in our study.
In apical variant, the hypertrophy predominantly involves 
the apical segments. Diagnostic criteria for apical HCM 
include an absolute apical wall thickness of >15 mm or a 
ratio comparing apical LV and basal LV wall thicknesses of 
≥1.3–1.5.[8,9] Apical HCM also called “Yamaguchi syndrome” 
is a relatively uncommon form of HCM. is variant is more 
frequent in the Japanese population. In this condition, there 
is obliteration of LV cavity at the apex, giving a characteristic 
spade-like configuration. In our study, apical variant was 
found in 6.8% (n = 5), which is a little higher than the figures 
reported from western countries (~2%) but significantly 
lower than that of Japan (~25%).[4,8]
In the variant with symmetrical hypertrophy, the 
hypertrophy involves the ventricular wall symmetrically with 
no regional preferences. LV cavity dimensions are reduced 
in a concentric fashion.[7,10] is entity should be evaluated 
closely to differentiate it from other causes of symmetric LV 
thickening.
On contrast enhanced CMR, areas of LGE can also be 
detected, which are considered to represent areas of fibrosis. 
Identification of fibrosis by LGE technique has prognostic 
significance in predicting adverse clinical outcomes. In our 
study, LGE was present in 75.7% cases, which is little higher 
than the figures reported in the literature. LGE was reported 
in 55% by Maron et al.,[11] 42% by Chan et al.,[12] 63% by 
O’Hanlon et al.,[13] 68% by Lyon et al.,[14] 66.2% by Ismail 
et al.,[15] and 68.9% by Klopotowski et al.[16] ere are only 
few studies on the Asian population and, to the best of our 
knowledge, no data are available on LGE in sub-continental 
South Asian HCM population. LGE was observed in 73% 
of study population in Japan by Hen et al.[17] Choi et al.[18] 
reported a significantly higher detection of LGE in 91.5% of 
study population in South Korea. e pooled prevalence of 
LGE was found to be 60% in a meta-analysis of four studies 
which evaluated 1063 patients.[19] e variable prevalence can 
be explained by the different study population, study designs, 
inter-observer variability, and LGE detection methods.
Most common location for LGE in our study was septum and 
LV free wall, which was also observed in studies by Maron 
et al. and Olivotto et al.[11,20] However, apex was the most 
common site in a study by Hen et al. in Japanese cohort.[17]
Severity of hypertrophy showed statistically significant 
association with the presence of LGE in our study, which 
is in agreement with the findings of studies by Ismail et al. 
and others.[11,15,20] Our study found a statistically significant 
association between LGE and LVOT obstruction, in contrast 
no such association was found by Maron et al.[11] Association of 
LGE with systolic dysfunction and lower EF was reported in the 
studies,[11,14,15] and similar findings were observed in our study.
A high rate of MACE was observed in our study population, 
which is similar to what Songsirisuk et al.[21] observed. 
Cardiovascular complications were reported in 47% of 
Chinese HOCM population by Ho et al.[22] and in 35.6% 
by Lee et al.[23] in Taiwan. However, in contrast lower rate 
was reported by studies in Europe and USA.[13,24,25] ese 
differences are probably due to the heterogeneous population, 
variable definition of MACE, rate of ICD insertion, and 
health-care resources. MACE were more common in patients 
with LGE, presence of LGE has been found to increase the 
risk of SCD, cardiovascular complications, and increase in 
all-cause mortality.[26,27]
e prevalence of RV involvement is 16.2% in our study which 
is similar to 18% reported in the literature.[4,7] is typically 
involves the mid-to-apical portion of the RV. RV involvement 
was also found to be associated with cardiovascular 
complications in our study and this was in agreement 
with various other studies,[28,29] in which RV involvement 
was associated with increased risk of sudden death and 
ventricular arrhythmias.
LVOT obstruction was present in 28.4% of the patients in our 
study, which is comparable to that found in the studies done by 
Songsirisuk et al. (24%) and Maron et al. (25%).[21,30] However, 
in a study done by Lee et al. on Taiwanese population, LVOT 
obstruction was demonstrated in a much higher percentage 
(48.1%) of HCM patients.[23]
LVOT obstruction was also associated with MACE[22] and 
was a strong, independent predictor of progression to severe 







LVEF 63.9±14.6 66.50±12.6 0.42
LV Mass 220.9±95.7 215.7±90.1 0.81
Age 42.8±17.5 47.5±14.2 0.21
LV ickness 22.4±5.5 20.3±4.9 0.09
LGE+ 27 (48.2%) 29 (51.8%) 0.018
LGE− 3 (16.7%) 15 (83.3%)
RV Involvement (+) 8 (66.7%) 4 (33.3%) 0.046*
RV Involvement (−) 22 (35.5%) 40 (64.5%)
LVOT+ 10 (47.6%) 11 (52.4%) 0.43
LVOT− 20 (37.7%) 33 (62.3%)
MACE: Major adverse cardiac events, CMR: Cardiac magnetic resonance, 
LVEF: Left ventricle ejection fraction, LV: Left ventricle, RV: Right 
ventricle, LGE: Late gadolinium enhancement
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symptoms of heart failure and death[30] in studies done by Ho 
et al. and Maron et al., respectively, which was not the case in 
our study group.
Limitations
Our study has several limitations; it is a retrospective, 
single-center study, resulting in a smaller sample size. LGE 
was assessed qualitatively and no quantification was done 
in terms of percentage of myocardium involved. e major 
limitation of this study is that the HCM has already been 
widely studied and the information is not especially novel 
with regard to the underlying condition. However, this is the 
first study of its kind from this region, which has evaluated 
the findings on CMR and cardiovascular complications in 
HCM patients.
Our hospital serves as the only center offering CMR facility 
to a large area of population and hence has been a referral 
center for CMR in patients with HCM. erefore, the 
results of this study may be representative of the Pakistani 
population with HCM.
CONCLUSION
Asymmetrical septal hypertrophy was the most common 
pattern of hypertrophy, followed by septal and anterior 
wall hypertrophy. LGE was present in three fourth of the 
study population, with patchy enhancement being the most 
common pattern. Patients with LGE were more likely to have 
systolic dysfunction and mean EF was found to be lower in 
patients with LGE. MACE (Death, heart Failure, and VT/VF) 
were observed in less than half of the patients. e presence 
of LGE and RV involvement was found to have statistically 
significant association with MACE.
Despite the limitations of this study, the presence of LGE 
seems to be a promising additional risk marker in predicting 
outcome in HCM patients, in this region too. After the 
availability of this local data, there should be no hesitancy 
in early use of CMR for diagnosis and risk stratification of 
patients with HCM in our population.
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